SSGJ-706 combination for advanced GI cancers
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, SSGJ-706, combined with other treatments for advanced stomach, colon, pancreatic, or esophageal cancer that cannot be removed by surgery. It's for people who have not had prior treatment for their advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have advanced stomach, colon, pancreatic, or esophageal cancer that cannot be removed by surgery
- You have not had any previous treatment for your advanced cancer (prior surgery or chemotherapy for earlier stage is okay)
- You have at least one tumor that can be measured on a scan
- You are willing to provide a sample of your tumor tissue for testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This trial tests a combination of three drugs—tislelizumab (immunotherapy), anlotinib (targeted therapy), and a chemotherapy regimen (S1 plus oxaliplatin)—given before surgery for locally advanced adenocarcinoma of the gastroesophageal junction. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new drug called SSGJ-707 for people with advanced endometrial cancer or ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if it can help shrink or slow down the cancer.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.